Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial - Takeaways - MDSpire

Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial

  • By

  • Jean-Marc Boivin

  • Joao Pedro Ferreira

  • Marilucy Lopez-Sublet

  • Kevin Duarte

  • Faiez Zannad

  • Patrick Rossignol

  • Nicolas Girerd

  • August 21, 2025

  • 0 min

Share

  • 1

    The STOP-Trial assessed the feasibility of discontinuing antihypertensive therapy (AHT) in patients with controlled hypertension.

  • 2

    Among 218 participants, 36% maintained normotension for one year after stopping AHT, while 64% required resumption of treatment.

  • 3

    Baseline home blood pressure measurements (HBPM) significantly predicted long-term blood pressure control after AHT discontinuation.

  • 4

    Patients with systolic HBPM < 120 mmHg had a 60% chance of maintaining normal blood pressure without treatment.

  • 5

    Discontinuing AHT may be considered for selected individuals with controlled hypertension and low baseline HBPM, with close monitoring.

Original Source(s)

Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial

  • by Jean-Marc Boivin, Joao Pedro Ferreira, Marilucy Lopez-Sublet, Kevin Duarte, Faiez Zannad, Patrick Rossignol, Nicolas Girerd

  • August 21, 2025

Related Content

An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.